LONDON (Alliance News) - ANGLE PLC Wednesday said that the University of Southern California's Norris Comprehensive Cancer Center will present "highly promising results" from its first phase of work with ANGLE's Parsortix system at the World CDX Conference in Boston.
The Cancer Center has been working with Parsortix, which is used to perform non-invasive liquid biopsies by capturing circulating tumour cells from a patients blood, in breast cancer. It has compared results from a liquid biopsy using Parsortix with results from a biopsy of metastatic sites in metastatic breast cancer patients.
Findings from the first four patients showed that in all of the patients the circulating tumour cells for the Parsortix liquid biopsy had similar patterns of gene expression to the traditional biopsy of cancer cells from metastatic sites.
"There is a significant need for simple and accurate diagnostics to support cancer therapy. We believe the Parsortix system offers a non-invasive medical approach that has the potential to transform the detection of cancer and significantly improve the treatment of cancer patients through precision medicine," said Chief Executive and Founder Andrew Newland in a statement.
Shares in ANGLE were up 3.1% at 81.97 pence Wednesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Angle (AGL)